AAAAAA
Results:
1-21
|
Results: 21
Authors:
Kehrer, DFS
Sparreboom, A
Verweij, J
de Bruijn, P
Nierop, CA
van de Schraaf, J
Ruijgrok, EJ
de Jonge, MJA
Citation: Dfs. Kehrer et al., Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients, CLIN CANC R, 7(5), 2001, pp. 1136-1141
Authors:
Yamamoto, W
Verweij, J
de Bruijn, P
de Jonge, MJA
Takano, H
Nishiyama, M
Kurihara, M
Sparreboom, A
Citation: W. Yamamoto et al., Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells, ANTI-CANC D, 12(5), 2001, pp. 419-432
Authors:
Eskens, FALM
Awada, A
Cutler, DL
de Jonge, MJA
Luyten, GPM
Faber, MN
Statkevich, P
Sparreboom, A
Verweij, J
Hanauske, AR
Piccart, M
Citation: Falm. Eskens et al., Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors, J CL ONCOL, 19(4), 2001, pp. 1167-1175
Authors:
de Jongh, FE
Verweij, J
Loos, WJ
de Wit, R
de Jonge, MJA
Planting, AST
Nooter, K
Stoter, G
Sparreboom, A
Citation: Fe. De Jongh et al., Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure, J CL ONCOL, 19(17), 2001, pp. 3733-3739
Authors:
Gelderblom, H
Sparreboom, A
de Jonge, MJA
Loos, WJ
Wilms, E
Mantel, MA
Hennis, B
Camlett, I
Verweij, J
van der Burg, MEL
Citation: H. Gelderblom et al., Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer, BR J CANC, 85(8), 2001, pp. 1124-1129
Authors:
Kehrer, DFS
Yamamoto, W
Verweij, J
de Jonge, MJA
de Bruijn, P
Sparreboom, A
Citation: Dfs. Kehrer et al., Factors involved in prolongation of the terminal disposition phase of SN-38: Clinical and experimental studies, CLIN CANC R, 6(9), 2000, pp. 3451-3458
Authors:
Loos, WJ
Gelderblom, H
Sparreboom, A
Verweij, J
de Jonge, MJA
Citation: Wj. Loos et al., Inter- and intrapatient variability in oral topotecan pharmacokinetics: Implications for body-surface area dosage regimens, CLIN CANC R, 6(7), 2000, pp. 2685-2689
Authors:
Gelderblom, H
Loos, WJ
Verweij, J
de Jonge, MJA
Sparreboom, A
Citation: H. Gelderblom et al., Topotecan lacks third space sequestration, CLIN CANC R, 6(4), 2000, pp. 1288-1292
Authors:
Verweij, J
de Jonge, MJA
Citation: J. Verweij et Mja. De Jonge, Achievements and future of chemotherapy, EUR J CANC, 36(12), 2000, pp. 1479-1487
Authors:
Loos, WJ
Gelderblom, HJ
Verweij, J
Brouwer, E
de Jonge, MJA
Sparreboom, A
Citation: Wj. Loos et al., Gender-dependent pharmacokinetics of topotecan in adult patients, ANTI-CANC D, 11(9), 2000, pp. 673-680
Authors:
Gelderblom, AJ
Loos, WJ
de Jonge, MJA
Sparreboom, A
Planting, AST
van der Burg, MEL
Brouwer, E
Verheij, C
Ouwens, L
Hearn, S
Verweij, J
Citation: Aj. Gelderblom et al., Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin, ANN ONCOL, 11(9), 2000, pp. 1205-1207
Authors:
de Jonge, MJA
Loos, WJ
Gelderblom, H
Planting, AST
van der Burg, MEL
Sparreboom, A
Brouwer, E
van Beurden, V
Mantel, MA
Doyle, E
Hearn, S
Ross, G
Verweij, J
Citation: Mja. De Jonge et al., Phase I pharmacologic study of oral topotecan and intravenous cisplatin: Sequence-dependent hematologic side effects, J CL ONCOL, 18(10), 2000, pp. 2104-2115
Authors:
de Jonge, MJA
Sparreboom, A
Planting, AST
van der Burg, MEL
de Boer-Dennert, MM
ter Steeg, J
Jacques, C
Verweij, J
Citation: Mja. De Jonge et al., Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors, J CL ONCOL, 18(1), 2000, pp. 187-194
Authors:
de Jonge, MJA
Verweij, J
de Bruijn, P
Brouwer, E
Mathijssen, RHJ
van Alphen, RJ
de Boer-Dennert, MM
Vernillet, L
Jacques, C
Sparreboom, A
Citation: Mja. De Jonge et al., Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin, J CL ONCOL, 18(1), 2000, pp. 195-203
Authors:
de Jonge, MJA
Verweij, J
Planting, AST
van der Burg, MEL
Stoter, G
de Boer-Dennert, MM
de Bruijn, P
Brouwer, E
Vernillet, L
Sparreboom, A
Citation: Mja. De Jonge et al., Drug-administration sequence does not change pharmacodynamics and kineticsof irinotecan and cisplatin, CLIN CANC R, 5(8), 1999, pp. 2012-2017
Authors:
Loos, WJ
Verweij, J
Gelderblom, HJ
de Jonge, MJA
Brouwer, E
Dallaire, BK
Sparreboom, A
Citation: Wj. Loos et al., Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans, ANTI-CANC D, 10(8), 1999, pp. 705-710
Authors:
Mathijssen, RHJ
van Alphen, RJ
de Jonge, MJA
Verweij, J
de Bruijn, P
Loos, WJ
Nooter, K
Vernillet, L
Stoter, G
Sparreboom, A
Citation: Rhj. Mathijssen et al., Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin, ANTI-CANC D, 10(1), 1999, pp. 9-16
Authors:
de Jonge, MJA
Punt, CJA
Gelderblom, AH
Loos, WJ
van Beurden, V
Planting, AST
van der Burg, MEL
van Maanen, LWGM
Dallaire, BK
Verweij, J
Wagener, T
Sparreboom, A
Citation: Mja. De Jonge et al., Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors, J CL ONCOL, 17(7), 1999, pp. 2219-2226
Authors:
Gelderblom, HAJ
de Jonge, MJA
Sparreboom, A
Verweij, J
Citation: Haj. Gelderblom et al., Oral topoisomerase 1 inhibitors in adult patients: Present and future, INV NEW DR, 17(4), 1999, pp. 401-415
Authors:
de Jonge, MJA
Verweij, J
Loos, WJ
Dallaire, BK
Sparreboom, A
Citation: Mja. De Jonge et al., Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva, CLIN PHARM, 65(5), 1999, pp. 491-499
Authors:
de Bruijn, P
de Jonge, MJA
Verweij, J
Loos, WJ
Nooter, K
Stoter, G
Sparreboom, A
Citation: P. De Bruijn et al., Femtomole quantitation of 7-ethyl-10-hydroxycamptothecine (SN-38) in plasma samples by reversed-phase high-performance liquid chromatography, ANALYT BIOC, 269(1), 1999, pp. 174-178
Risultati:
1-21
|